je.st
news
Tag: approves
FDA Approves Mercks KEYTRUDA (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
2016-08-08 12:45:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor:Teri Loxam, 908-740-1898orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Federal government approves trial to fight Zika in Key West, but residents can still hold it up
2016-08-07 16:00:00| Climate Ark Climate Change & Global Warming Newsfeed
Tampa Bay Times: The federal government on Friday approved a field trial that would release millions of genetically-modified mosquitoes in Key West to eradicate the mosquito that carries Zika. But British company Oxitec, which has already used its technology to reduce the Aedes aegypti population by 90 to 99 percent in parts of Latin America, is still held up by residents of a Key West suburb who are skeptical of the science. In a statement, the U.S. Food and Drug Administration said Friday the Oxitec trial...
FDA Approves Mercks KEYTRUDA (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
2016-08-06 01:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor:Teri Loxam, 908-740-1898orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Canadas NEB approves TransCanadas proposal for gas pipeline construction
2016-08-05 01:00:00| Hydrocarbons Technology
Canadas National Energy Board (NEB) has issued a letter conditionally approving TransCanada PipeLines application for the construction and operation of approximately 11.7km of new natural gas pipeline in Vaughan, Ontario.
Tags: construction
gas
proposal
pipeline
Indian govt approves spectrum usage charge
2016-08-04 02:00:00| Total Telecom industry news
Cabinet approval means DoT can invite applications to take part in upcoming spectrum auction.
Tags: charge
usage
indian
spectrum
Sites : [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] next »